A Rare Gene Change Cut Weight Loss on Semaglutide Far More Than on Tirzepatide
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link

If you've been taking Ozempic or Wegovy and the scale has barely moved, you may have wondered if you're doing something wrong or if the medication just doesn’t work for you. A new study suggests that for a small number of people, the reason could be in their genes.
Researchers found that people with a rare change in one gene lost much less weight on semaglutide. On tirzepatide, their results were much closer to those of similar people without the gene change. It's early research in a small group, but it might be a good thing to bring up with your clinician if you find you’re in the same boat.
Who This Helps
This is for anyone on semaglutide who's lost less weight than they expected. It's also for anyone deciding between semaglutide and tirzepatide.
What did the study look at?
The study was published in Nature Metabolism in November 2026. Researchers looked at health records and DNA test results for 13,725 adults taking weekly shots of semaglutide or tirzepatide (Nature Metabolism).
Semaglutide is the drug in Ozempic and Wegovy. Tirzepatide is the drug in Mounjaro and Zepbound.
The researchers focused on one gene. It holds the instructions for the GLP-1 receptor, the spot on your cells where these drugs attach to do their work.
Some people have one of several rare changes in that gene that may make the receptor work not as well. In this post, we call any of those "the gene change." It was rare in the study, showing up in about 2 of every 1,000 people.
What did the researchers find?
Each person with the gene change was compared with similar people without it. They were matched on things like drug, dose, sex, starting weight for their height and whether they had type 2 diabetes. The researchers then looked at each person's biggest weight loss between months 6 and 12.
On semaglutide, the difference was large. People with the gene change lost 2.4% of their body weight. Similar people without the gene change lost 8.8%.
On tirzepatide, the two groups were much closer. People with the gene change lost 13.3% of their body weight on average, compared with 15.2% for similar people without it. That gap was small enough that it could have been chance, but it needs to be studied further.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Why would tirzepatide work differently?
Semaglutide works through one receptor, the GLP-1 receptor. Tirzepatide works through two: the GLP-1 receptor and a second one called the GIP receptor.
The researchers think the second receptor may help make up the difference when the first one isn't working well. They haven't proven that yet, and they say it needs to be tested in the lab.
Tirzepatide didn't close the gap for everyone. A handful of people had gene changes predicted to do the most harm. They lost about a third less weight on tirzepatide than similar people without the gene change. The researchers call that an early clue that needs more study.
How sure can we be about this?
This is one small study. Only 17 people with the gene change took semaglutide, and 19 took tirzepatide. A few took both drugs at different times and were counted in both groups. With groups this small, a few unusual results can shift the averages.
The study used everyday health records, and nobody was randomly assigned a drug. Missed doses and weigh-ins weren't always recorded. So the results are less certain than a clinical trial's would be.
Most people in the study were of European ancestry, so the results may not hold for everyone. And only some of the gene changes have been confirmed in a lab. The rest were picked using computer predictions.
Two smaller groups of patients showed the same pattern on semaglutide. But they were tiny, with 8 and 7 people with the gene change. One came from the same health systems as the main study, and the other's result could have been chance.
Eight of the study's 21 authors work for Helix, the company that ran the DNA tests and the research network behind the study. Helix staff also designed the study and ran the numbers. Other research teams still need to test the finding.
Does this explain why semaglutide isn't working for you?
Probably not. The gene change is rare, and most slow results have more common causes. Not being on the full dose yet, not being on it long enough, other medicines that can cause weight gain, and some health conditions can all play a part.
Still, the study suggests that a slow response on semaglutide can have a biological cause. It isn't always about effort. Our earlier post on GLP-1 genetics covers other gene research on this question.
Can you get tested for the gene change?
Not as part of regular care right now. The study used a detailed DNA test from a medical lab. But no treatment guideline we could find says prescribers should use this gene to choose between these medications. The finding is too new and too small to act on yet.
Some companies now sell GLP-1 gene reports directly to patients. The ones we found focus on more common gene changes, and we couldn't confirm that any of them looks for these rare ones. Standard at-home DNA kits can miss rare changes too, so a kit may not tell you anything about this finding.
What should you ask your prescriber?
You don't need a gene test to have a useful conversation. If you've been on semaglutide for several months at a steady dose and haven't lost much, you can ask:
- Is my dose where it should be, and have I been on it long enough to judge?
- Could anything else be slowing my results?
- Would a different medication make sense for me?
Switching is a decision to make with your prescriber. It can depend on your health history, side effects, cost and insurance coverage. This study also didn't follow people who switched from one drug to the other, so don't stop or change your medication on your own.
Final Takeaway
For a small number of people, a rare gene change may explain why semaglutide leads to less weight loss. In this study, their results on tirzepatide were much closer to other people's on average. The study was small, and there's no routine test for the gene change yet. If semaglutide isn't working well for you, talk with your prescriber about your options.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Why am I not losing weight on semaglutide?
There are many possible reasons, including dose, time on the medication, other medicines and health conditions. A new study suggests a rare gene change may be one reason for a small number of people.
Does tirzepatide work if semaglutide doesn't?
Sometimes. In a large trial of people new to both drugs, tirzepatide led to more weight loss on average. That isn't the same as switching after semaglutide didn't work, and the new gene study didn't follow anyone who switched. Ask your prescriber whether switching makes sense for you.
Is there a genetic test for GLP-1 response?
Not one that's part of regular care. Some companies sell GLP-1 gene reports, but we couldn't find a treatment guideline that recommends gene testing before choosing a GLP-1.
How common is the gene change in this study?
It's rare. About 2 in every 1,000 people in the study had it.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Keep Reading

Peptide cycling is popular online, but research is thin. Learn where the idea came from and why your prescriber should set how long you take one.

The FDA is requiring a NAION warning on every GLP-1. How rare it is, which symptoms mean call right away, and why not to stop on your own.

A Nov 2026 study linked GLP-1s to 31% fewer new diabetes cases than metformin in adults with prediabetes. What it shows, limits, what to ask.
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner, where she works on marketing, content creation, and operations. She has over 10 years' experience in the content creation space, including in the GLP-1 space, where she works to stay on top of access news, research updates, and lifestyle tips guided by science.